Tower Research Capital (TRC)’s Urovant Sciences Ltd. UROV Stock Holding History

Tower Research Capital (TRC)’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-638	Closed	-$10K	–	6007
2020 Q4	$10K	Buy	+638	New	+$7.91K	﹤0.01%	4359
2020 Q3	–	Sell	-649	Closed	-$6K	–	5287
2020 Q2	$6K	Buy	+649	New	+$6.22K	﹤0.01%	4251
2020 Q1	–	Sell	-1,735	Closed	-$27K	–	4333
2019 Q4	$27K	Buy	+1,735	New	+$18.8K	﹤0.01%	1748
2019 Q3	–	Sell	-914	Closed	-$7K	–	4748
2019 Q2	$7K	Sell	914 -440	-32%	-$3.61K	﹤0.01%	2809
2019 Q1	$14K	Sell	1,354 -1,626	-55%	-$16.7K	﹤0.01%	2502
2018 Q4	$20K	Buy	+2,980	New	+$27.1K	﹤0.01%	1962

Tower Research Capital (TRC)'s UROV Position: Q1 2021 in Review

Tower Research Capital (TRC) sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 638 shares — an estimated $10K sold.

Tower Research Capital (TRC) first reported a position in UROV in Q4 2018 and held it in 6 quarters. The position peaked at $27K in Q4 2019. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Tower Research Capital (TRC) reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Tower Research Capital (TRC) sold 638 Urovant Sciences Ltd. shares in Q1 2021, an estimated $10K.
Tower Research Capital (TRC) first reported a position in Urovant Sciences Ltd. in Q4 2018 and held it in 6 quarters.
Tower Research Capital (TRC)'s Urovant Sciences Ltd. position peaked at $27K in Q4 2019.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.